AstraZeneca bets on continued oncology demand for 2026 growth

AstraZeneca expects profits to summation successful 2026, arsenic it counts connected beardown request for its oncology portfolio continuing contempt geopolitical pressures and patent expiry headwinds.

AstraZeneca reported afloat twelvemonth 2025 gross of $58.7bn, up 8% astatine changeless speech complaint (CER) compared to 2024. Oncology cause income were a large operator for the drugmaker’s growth, with gross successful the concern expanding 14% to $25.6bn successful 2025 compared to the twelvemonth before.

Lung crab cause Tagrisso (osimertinib) was the top-selling merchandise successful the oncology segment, generating $7.25bn successful income for the year. Immunotherapy Imfinzi netted $6.06bn successful 2025, boosted by US approvals successful bladder crab and gastric and gastroesophageal junction (GEJ) cancers. Sales for HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) saw a important income increase, surging 40% to scope $2.78bn successful 2025.

In an net call, Imfinzi and Enhertu were earmarked by AstraZeneca’s elder enactment squad arsenic cardinal gross drivers for 2026, boosted by caller and upcoming crab denotation expansions.

Enhertu, co-marketed with Daiichi Sankyo, is forecast to make planetary income of $14.3bn successful 2031, according to investigation by GlobalData.

GlobalData is the genitor institution of Pharmaceutical Technology.

With assurance successful the continued spot of oncology sales, on with a divers pipeline that includes an oral obesity pill acceptable to participate Phase III trials, AstraZeneca issued a dependable maturation forecast for 2026.

Total gross is expected to summation by a mid-to-high single-digit percentage, portion halfway net per stock (EPS) is expected to summation by a debased double-digit percentage.

In the net call, main fiscal serviceman Aradhana Sarin said that impacts from President Trump’s Most Favored Nation (MFN) argumentation had already been modelled successful the forecast. AstraZeneca, the UK’s astir invaluable company, became the archetypal non-US drugmaker to motion a pricing woody with the White House successful October 2025. In exchange, the institution is exempt from tariffs for 3 years.

Citi analysts said the 2025 results and 2026 guidance were some broadly in-line with consensus. They commented that it was “overall a coagulated acceptable of results and reassuring guidance… [with a] wealthiness of pipeline quality flow”.

Shares successful London-listed AstraZeneca roseate 0.4% to £13,952 astatine marketplace unfastened connected 10 February compared to £13,888 astatine marketplace adjacent connected 9 February. The company’s banal worth has continued passim 10 February. The drugmaker has a marketplace headdress of £216.1bn.

CEO Pasal Soriot is targeting yearly income of $80bn by 2030, driven by anticipated launches and broader institution development.